Joseph Manni Sells 768 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CRO Joseph Manni sold 768 shares of the company’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $19.79, for a total transaction of $15,198.72. Following the completion of the transaction, the executive directly owned 26,933 shares in the company, valued at $533,004.07. This trade represents a 2.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

CeriBell Stock Down 4.8%

CBLL traded down $0.95 during trading on Wednesday, reaching $18.95. 713,550 shares of the stock traded hands, compared to its average volume of 351,326. The stock’s 50-day simple moving average is $21.26 and its two-hundred day simple moving average is $16.17. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25. CeriBell, Inc. has a fifty-two week low of $10.01 and a fifty-two week high of $25.98. The stock has a market cap of $703.05 million, a price-to-earnings ratio of -12.55 and a beta of 1.03.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. The company had revenue of $24.78 million during the quarter, compared to the consensus estimate of $23.95 million. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%. As a group, equities research analysts expect that CeriBell, Inc. will post -2.46 EPS for the current year.

More CeriBell News

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Q4 beat on both EPS and revenue — CeriBell reported a loss of ($0.36) vs. consensus ($0.43) and revenue of $24.78M vs. $23.95M expectations, showing top‑line strength and a smaller-than-expected loss. Zacks: Q4 results
• Positive Sentiment: Management highlighted market expansion and revenue acceleration on the earnings call, which supports ongoing growth expectations for newborn hearing-screening adoption. Earnings call transcript
• Neutral Sentiment: FY2026 revenue guidance of $111.0M–$115.0M was issued, roughly in line with the Street estimate (~$112.7M) — guidance supports growth but isn’t a clear upside surprise. (Press release/earnings coverage.)
• Neutral Sentiment: Balance-sheet strength: very high current and quick ratios indicate ample liquidity, reducing short-term financing risk. (See filings/coverage.)
• Negative Sentiment: Insider selling: Director Josef Parvizi sold 16,714 shares (recently continued a pattern of sales), which can be viewed negatively by some investors. Insider selling report
• Negative Sentiment: Company remains unprofitable with a negative net margin (~‑63%), negative ROE, and an expected full‑year EPS loss — profitability timeline remains a key risk for valuation. Business Insider: results summary
• Negative Sentiment: Mixed analyst moves — at least one price-target cut alongside continued buy ratings elsewhere creates divergent expectations that can increase volatility. (Analyst coverage summarized in public filings/press coverage.)

Analyst Ratings Changes

Several research analysts have recently commented on CBLL shares. TD Cowen restated a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. Canaccord Genuity Group increased their target price on shares of CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. JPMorgan Chase & Co. decreased their price target on CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Finally, BTIG Research reissued a “buy” rating and set a $30.00 price objective on shares of CeriBell in a report on Wednesday, January 28th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $24.67.

Institutional Investors Weigh In On CeriBell

A number of hedge funds have recently bought and sold shares of CBLL. Bank of New York Mellon Corp grew its position in CeriBell by 1,945.9% during the fourth quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after buying an additional 1,162,200 shares in the last quarter. KCM Capital Inc acquired a new position in CeriBell in the 4th quarter valued at approximately $21,930,000. Royce & Associates LP bought a new stake in shares of CeriBell in the 4th quarter worth approximately $11,695,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of CeriBell during the 4th quarter worth approximately $10,965,000. Finally, CenterBook Partners LP increased its position in shares of CeriBell by 448.0% during the third quarter. CenterBook Partners LP now owns 476,554 shares of the company’s stock valued at $5,476,000 after purchasing an additional 389,584 shares during the period.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.